Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $12.00 | Underperform | Leerink Partners |
| 3/26/2025 | $23.00 → $35.00 | Neutral → Buy | Citigroup |
| 3/21/2025 | Overweight | Cantor Fitzgerald | |
| 3/12/2025 | $30.00 | Outperform | Evercore ISI |
| 2/28/2025 | $42.00 | Buy | Goldman |
| 1/8/2025 | $35.00 | Buy | Truist |
| 12/11/2024 | $30.00 | Overweight | Wells Fargo |
| 12/6/2024 | $31.00 | Buy | Jefferies |
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 71,275 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on June 2, 2025. The options have a ten (10) year term and an exercise price of $17.72 per share, the closing price per share of the Company's common stock as reported by Nasdaq on June
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the progress of our organization, including the development of our innovative investigational bispecific antibody, ivonescimab. The presentation will be available live from our website: www.smmttx.com. An archived version of the presentation will be available on our website following the presentation. About Summ
Consistent Results Noted between Single Region HARMONi-A and Multiregional HARMONi Studies; Favorable Trends in Sub-Populations from North America and China for Both Primary Endpoints Were Observed Ivonescimab in Combination with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone; Positive Overall Survival Trend Observed with Hazard Ratio of 0.79 HARMONi Represents the First Phase III Trial to Evaluate Ivonescimab in a Multiregional Setting Summit to Determine Timing of US BLA Filing Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced topline results from the Phase III clinical trial, HARMONi, the
Leerink Partners initiated coverage of Summit Therapeutics with a rating of Underperform and set a new price target of $12.00
Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously
Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight